Another study showed that MSCs, which expressed anti-PSA antibody and BH3-interacting domain death agonist (BID, a member of Bcl-2 protein family) fusion protein, could be used to treat prostate cancer [23]. The gene discussed is BCL2; the disease is Familial prostate cancer.